Is there a role for genetic risk assessment in the treatment of dyslipidemia in primary and secondary prevention of coronary heart disease?

Jassim Al Suwaidi

doi:10.5339/gcsp.2015.19

ISSN: 2305-7823
EISSN:

oa Is there a role for genetic risk assessment in the treatment of dyslipidemia in primary and secondary prevention of coronary heart disease?
By Jassim Al Suwaidi¹
View Affiliations Hide Affiliations

Affiliations: ¹ Qatar Cardiovascular Research Center and Adult Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar
Source: Global Cardiology Science and Practice, Volume 2015, Issue 2, Jun 2015,
DOI: https://doi.org/10.5339/gcsp.2015.19
- Received: 12 March 2015
- Accepted: 30 April 2015
- Published online: 23 June 2015

Abstract

Genetic variants have been associated with the risk of coronary heart disease (CHD). Mega et al studied the association of a genetic risk score based on 27 genetic variants with incidents of recurrent CHD, adjusting for traditional risk factors using data from a community based study and 4 randomized controlled trials of both primary and secondary prevention with statin therapy. When individuals were divided into low, intermediate and high genetic risk categories, a significant gradient in risk of incident and recurrent CHD was shown.

Article metrics loading...

/content/journals/10.5339/gcsp.2015.19

2015-06-23

2021-05-07

Full text loading...

/deliver/fulltext/gcsp/2015/2/gcsp.2015.19.html?itemId=/content/journals/10.5339/gcsp.2015.19&mimeType=html&fmt=ahah

References

Schunkert H, Samani NJ. Statin treatment: can genetics sharpen the focus? Lancet. 2015 Mar 3.
[Google Scholar]
Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield MJ, Devlin JJ, Nordio F, Hyde CL, Cannon CP, Sacks FM, Poulter NR, Sever PS, Ridker PM, Braunwald E, Melander O, Kathiresan S, Sabatine MS. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015 Mar 3;, pii: S0140-6736(14)61730-X.
[Google Scholar]
Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman M, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood DESC/EAS. Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011; 32::1769–1818.
[Google Scholar]
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63:25:2889–2934.
[Google Scholar]

http://instance.metastore.ingenta.com/content/journals/10.5339/gcsp.2015.19

Article Type: Research Article

oa Is there a role for genetic risk assessment in the treatment of dyslipidemia in primary and secondary prevention of coronary heart disease?

Abstract

Most Read This Month